What would you like to look for?
Site search

20 December 2021

deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization has been acquired by Alloy Therapeutics, a biotechnology ecosystem company. The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles. The company is a spinoff of ETH Zurich and Department of Biosystems Science and Engineering. VISCHER has been advising deepCDR Biologics since foundation as well as on all legal issues related to the sale to Alloy Therapeutics. The VISCHER team includes Matthias Staehelin, Pauline Pfirter and Timothy Woodtli (all Corporate/M&A).

Press release

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions

You are currently offline. Some pages or content may fail to load.